NL-OMON38040已完成3 期
A randomized, double-blind, placebo-controlled phase IIIa study of bIAP, an anti-inflammatory moiety, in patients undergoing combined aortic valve replacement and coronary artery bypass grafting. - APPIRED II
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Patients planned for combined AVR and CABG surgery
排除标准
- •base alkaline phosphatase levels (>125 IU/L)
- •significant hepatic disease
- •renal insufficiency
- •scheduled to receive stress doses of glucocrticoids
- •vegetarians or intolerant for bovine products
研究者
相似试验
进行中（未招募）
1 期
A study to test whether pazopanib can prevent or delay kidney tumor coming back after the tumor has been removedRenal Cell CarcinomaEUCTR2010-020965-26-SKovartis Pharma Services AG1,500
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib - BAY73-4506 Phase III GIST 3rd/4th lineEUCTR2009-017957-37-FRBayer HealthCare AG170
进行中（未招募）
1 期
Study of Reparixin combined with paclitacel compared to paclitaxel alone in patients with metastatic Triple-negative breast cancerEUCTR2014-004796-23-PLDompé Farmaceutici s.p.a.123
进行中（未招募）
1 期
16-week efficacy and 3-year safety, tolerability and efficacy of secukinumab in active ankylosing spondylitis patientsEUCTR2013-001090-24-BEovartis Pharma Services AG222
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy, safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor agonist, administered for 6 months as oral tablets once daily in adult subjects with previously treated chronic idiopathic thrombocytopenic purpura (ITP). - RAISEEUCTR2006-000470-78-FRGlaxoSmithKline Research and Development Limited